Discovery of N-(4-Aminobutyl)-N’-(2-methoxyethyl)guanidine as the First Selective, Nonamino Acid, Catalytic Site Inhibitor of Human Dimethylarginine Dimethylaminohydrolase-1 (hDDAH-1) was written by Lunk, Ina;Litty, Felix-Alexander;Hennig, Sven;Vetter, Ingrid R.;Kotthaus, Juerke;Altmann, Karin S.;Ott, Gudrun;Havemeyer, Antje;Garcia, Carmen Carrillo;Clement, Bernd;Schade, Dennis. And the article was included in Journal of Medicinal Chemistry in 2020.SDS of cas: 4457-67-4 This article mentions the following:
N-(4-Aminobutyl)-N’-(2-methoxyethyl)guanidine (8a) is a potent inhibitor targeting the hDDAH-1 active site (Ki = 18μM) and derived from a series of guanidine- and amidine-based inhibitors. Its nonamino acid nature leads to high selectivities toward other enzymes of the nitric oxide-modulating system. Crystallog. data of 8a-bound hDDAH-1 illuminated a unique binding mode. Together with its developed N-hydroxyguanidine prodrug 11, 8a will serve as a most widely applicable, pharmacol. tool to target DDAH-1-associated diseases. In the experiment, the researchers used many compounds, for example, 1-Bromo-4-methoxybutane (cas: 4457-67-4SDS of cas: 4457-67-4).
1-Bromo-4-methoxybutane (cas: 4457-67-4) belongs to organobromine compounds. A variety of minor organobromine compounds are found in nature, but none are biosynthesized or required by mammals. Organobromine compounds have fallen under increased scrutiny for their environmental impact. The reactivity of organobromine compounds resembles but is intermediate between the reactivity of organochlorine and organoiodine compounds. For many applications, organobromides represent a compromise of reactivity and cost.SDS of cas: 4457-67-4
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary